Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in china

Emerging Microbes and Infections

Volumn 3, Issue , 2014, Pages

  Wang, Xiang ^a,b   Xing, Man ^b   Zhang, Chao ^b   Yang, Yong ^b   Chi, Yudan ^b   Tang, Xinying ^b   Zhang, Hongbo ^b   Xiong, Sidong ^a   Yu, Luogang ^c   Zhou, Dongming ^b  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b INSTITUTE PASTEUR OF SHANGHAI   (China)

^c Department of Epidemiology   (China)

Author keywords

AdC7; AdHu5; CA16; EV71; hand, foot and mouth disease; neutralizing antibody; seroprevalence

Indexed keywords

NEUTRALIZING ANTIBODY;

ADENOVIRUS; ADENOVIRUS INFECTION; ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHIMPANZEE ADENOVIRUS PAN7; CHINA; COXSACKIE VIRUS 16; ENTEROVIRUS; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HUMAN; HUMAN ADENOVIRUS 5; IMMUNITY; MALE; NONHUMAN; NORMAL HUMAN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SERODIAGNOSIS; SEROPREVALENCE; SEROTYPE; TREND STUDY;

EID: 84900012821     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.30     Document Type: Article

References (42)

1. Yu H, Wang M, Chang H et al. Prevalence of antibodies against enterovirus 71 in children from Luan City in Central China. Jpn J Infect Dis 2011; 64: 528-532.
2. ToyaM, Endo Y, Tanizaki H, Fujisawa A, Tanioka M, Miyachi Y. An adult case of severe hand-foot-mouth disease accompanying persistent fever and systemic arthritis. Dermatol Online J 2012; 18: 14.
3. Hamaguchi T, Fujisawa H, Sakai K et al. Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis 2008; 14: 828-830.
4. Yang F, Ren L, Xiong Z et al. Enterovirus 71 outbreak in the Peoples Republic of China in 2008. J Clin Microbiol 2009; 47: 2351-2352.
5. DeW, Changwen K,Wei L et al. A large outbreak of hand, foot, and mouth disease caused by EV71 and CAV16 in Guangdong, China, 2009. Arch Virol 2011; 156: 945-953.
6. JiH, Li L, LiuYet al. Seroepidemiology of human enterovirus 71 and coxsackievirusA16 in Jiangsu province, China. Virol J 2012; 9: 248.
7. Rabenau HF, Richter M, Doerr HW. Hand, foot and mouth disease: Seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 2010; 199: 45-51.
8. Chen X, Wang C, Xu L et al. A laboratory evaluation of medicinal herbs used in china for the treatment of hand, foot, and mouth disease. Evid Based Complement Alternat Med: ECAM 2013; 2013: 504563.
9. Zeng M, El Khatib NF, Tu S et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol 2012; 53: 285-289.
10. Zhu FC, Liang ZL, Meng FY et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PloS ONE 2012; 7: E37206.
11. Luo ST, Chiang PS, Chao AS et al. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis 2009; 15: 581-584.
12. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 2003; 9: 78-85.
13. Ruohola A, Waris M, Allander T, Ziegler T, Heikkinen T, Ruuskanen O. Viral etiology of common cold in children, Finland. Emerg Infect Dis 2009; 15: 344-346.
14. Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet 1999; 354: 987-991.
15. Catanzaro AT, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replicationdefective recombinant adenovirus vector. J Infect Dis 2006; 194: 1638-1649.
16. McElrath MJ, De Rosa SC, Moodie Z et al.HIV-1 vaccine-induced immunity in the testof-concept Step Study: A case-cohort analysis. Lancet 2008; 372: 1894-1905.
17. Xiang Z, Gao G, Reyes-Sandoval A et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002; 76: 2667-2675.
18. Xiang Z, Li Y, Cun A et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006; 12: 1596-1599.
19. Shi J, Huang X, LiuQ, Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 2013; 31: 2130-2136.
20. Ku Z, Ye X, Huang X et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus genotype C4 inhibit infection at pre-and post-attachment steps. PloS ONE 2013; 8: E57601.
21. Sprangers MC, Lakhai W, Koudstaal W et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003; 41: 5046-5052.
22. Zhang S, Huang W, Zhou X, Zhao Q, Wang Q, Jia B. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol 2013; 85: 1077-1084.
23. Davenport CB. Analysis of variance applied to human genetics. Proc Natl Acad Sci USA 1940; 1: 1-3.
24. Spearman C. The proof and measurement of association between two things. Int J Epidemiol 2010; 5: 1137-1150.
25. Diedrich S, Weinbrecht A, Schreier E. Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol 2009; 154: 1139-1142.
26. Zhu Z, Zhu S, Guo X et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J 2010; 7: 300.
27. Chang LY, Hsiung CA, Lu CY et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 2006; 60: 466-471.
28. Yang C, Deng C, Wan J, Zhu L, Leng Q. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J 2011; 8: 306.
29. Fox JP, Hall CE, Cooney MK. The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 1977; 105: 362-386.
30. Thorner AR, Vogels R, Kaspers J et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006; 44: 3781-3783.
31. Kostense S, Koudstaal W, Sprangers M et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004; 18: 1213-1216.
32. Mast TC, Kierstead L, Gupta SB et al. International epidemiology of human preexisting adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28: 950-957.
33. Nwanegbo E, Vardas E, GaoWet al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11: 351-357.
34. Sumida SM, Truitt DM, Lemckert AA et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174: 7179-7185.
35. Pilankatta R, Chawla T, Khanna N, Swaminathan S. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol 2010; 82: 407-414.
36. Abbink P, Lemckert AA, Ewald BA et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81: 4654-4663.
37. Dudareva M, Andrews L, Gilbert SC et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009; 27: 3501-3504.
38. Yu B, Zhou Y, Wu H et al. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J Med Virol 2012; 84: 1408-1414.
39. Sun C, Zhang Y, Feng L et al. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine 2011; 29: 3837-3841.
40. Roy S, Kobinger GP, Lin J et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007; 25: 6845-6851.
41. Kobinger GP, Figueredo JM, Rowe T et al. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine 2007; 25: 5220-5231.
42. Kobinger GP, Feldmann H, Zhi Y et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006; 346: 394-401.